Supporting Information

1. Figures and Tables

- Fig. S1 Bar graph showing the $\Delta\delta H\alpha$ values ($\Delta\delta H\alpha = \delta H\alpha observed \delta H\alpha RC$, ppm) as a function of residue number for peptides **11** (in black) and **8a** (in grey). The chemical shift values reported for Wishart et al. 1995 for unstructured hexapeptides were taken as reference for the random coil state ($\delta H\alpha RC$).
- Fig. S2 Superimposition of the best two calculated structures of peptide **8a** and **11** with the α -helix Pro435-Met447 of Li-TryR.
- Fig. S3 Relative loss of binding (%) observed for the cyclic peptides 8 (*E* and *Z* isomers) and 11 (amide) with the Li-TryR monomer along the respective MD simulations when the total binding energy is compared with linear counterpart 2 under the same simulation conditions.
- Fig. S4 Detail of the representative structure of the major clusters calculated along the last 20 ns of the MD trajectories of peptide **2**, **8a**, **8b** and **11**.
- Fig. S5 Proteolytic stability of peptides 2, 5a and 11.
- Table S1Structural statistics for the ensemble of the 20 lowest target function NMR
structures of peptides 8a and 11.
- Table S2Total and per-residue binding energies (kcal mol⁻¹) calculated with MM-ISMSA
after analyzing the corresponding MD simulations of the system peptide:Li-
TryR monomer.

2. Chemistry

- 2.1. Assymptic synthesis of the α, α -disubstituted amino acids (S)-3 and (R)-4 (Scheme 1)
- 2.2. ¹H- and ¹³C-NMR chemical shifts (δ) of stapled peptides **5a**, **8a** and **11** (Tables S3-S5)
- 2.3. HPLC chromatograms, HRSM spectra and NMR spectra.



Fig. S1. Bar graph showing the $\Delta\delta H\alpha$ values ($\Delta\delta H\alpha = \delta H\alpha observed - \delta H\alpha RC$, ppm) as a function of residue number for peptides **11** (in black) and **8a** (in grey). The chemical shift values reported for Wishart et al. 1995 for unstructured hexapeptides were taken as reference for the random coil state ($\delta H\alpha^{RC}$).



Fig. S2 Superimposition of the best two calculated structures of peptide 8a (carbon atoms coloured in orange) and 11 (carbon atoms coloured in yellow) with the α -helix Pro435-Met447 (green) of Li-TryR (PDB id. 2JK6).



Fig. S3. Relative loss of binding (%) observed for the cyclic peptides 8 (E and Z isomers) and 11 (amide bridges) with the Li-TryR monomer along the respective MD simulations when the total binding energy is compared with linear counterpart 2 under the same simulation conditions.



Fig. S4. Detail of the representative structure of the major clusters calculated along the last 20 ns of the MD trajectories of peptide **2**, **8a**, **8b** and **11** (carbon atoms coloured in grey) using the module ptraj implement in the AmberTools 14.



Fig. S5 Proteolytic stability of peptide 2 (linear), 5a (all-hydrocarbon) and 11 (lactambridged).

		8a	11
Number of distance restraints	Intraresidue $(i - j = 0)$	48	50
	Sequential $(i - j = 1)$	38	31
	Medium range (1 < i – j < 5)	13	11
	Total number	99	92
Number of dihedral angle constraints	φ angles	12	12
	ψ angles	10	12
	Total number	22	24
Average maximum violations per structure	Distance (Å)	0.04±0.00	0.00±0.00
	Dihedral angle (°)	0.2 ± 0.2	0.00 ± 0.00
Averaged structure energies	CYANA target function value	0.23±0.02	$2 10^{-9} \pm 2$ 10^{-9}
Pairwise RMSd (Å)	Backbone atoms	0.5 ± 0.2	0.6 ± 0.2
	All heavy atoms	1.3 ± 0.2	1.4 ± 0.2
Ramachandran plot (%)	Residues in most favoured regions	100	100
	Residues in additional allowed regions	0.0	0.0
	Residues in generously allowed regions	0.0	0.0
	Residues in disallowed regions	0.0	0.0

 Table S1. Structural statistics for the ensemble of the 20 lowest target function NMR structures of peptides 8a and 11.

Table S2. Total and per-residue binding energies (kcal mol⁻¹) calculated with MM-ISMSA after analyzing the corresponding MD simulations of the system peptide:Li-TryR monomer. Only the last 20 ns of the 30 ns of each MD trajectories have been taken into account.

2	8 a	8 b	11
(linear prototype)	(E isomer)	(Z isomer)	(amide)
-73.8 ± 4.4	-52.1 ± 6.1	-55.6 ± 4.1	-63.7 ± 5.7

Total energy (kcal mol⁻¹)

Energy per residue (kcal mol⁻¹)

2	2 8a 8b		b	11			
(linear pr	cototype)	$(E \operatorname{isc}$	mer) (<i>E</i> isomer)		omer)	(am)	ide)
Residue	Energy	Residue	Energy	Residue	Energy	Residue	Energy
D453	-6.1	S440	-5.2	T457	-4.3	V460	-6.7
<i>I437</i>	-5.8	T457	-5.0	<i>I437</i>	-4.1	<i>I458</i>	-4.8
T457	-5.7	V460	-4.8	T463	-4.0	<i>C444</i>	-4.8
V460	-5.2	<i>I437</i>	-4.1	F454	-3.7	T457	-4.7
S440	-4.5	T463	-3.1	S440	-3.4	<i>I437</i>	-4.4
T463	-3.8			E436	-3.1	S440	-4.4
F454	-3.7					T463	-3.8
L468	-3.5					D453	-3.4
C444	-3.4						
V441	-3.0						

2. CHEMISTRY

2.1. Asymmetric synthesis of the α, α -disubstituted amino acids (S)-3 and (R)-4.

Starting from the commercially available chiral diphenyloxazinones **12** and **13**, the procedure described by described by Williams and colleges⁶¹ taking into account the modifications reported by Verdine group⁵⁴ was followed.



Scheme S1. Assymetric synthesis of quaternary amino acids (S)-3 and (R)-4.

(*3S*,*5S*,*6R*)-5,6-diphenyl-4-(*terc*-butoxycarbonyl)-3-methyl-2,3,5,6-tetrahydro-4*H*-1,4-oxazin-2-one (14)⁶.



White solid (80%). **M.p.** (hexane:AcOEt, 4:1): 201-202 °C M.p. ref. 202-204 °C. **HPLC** (Agilent, 10% to 100% of water in 10 min): 9.91 min (> 98% analytical purity). $[\alpha]^{rt}_{D}$ -65.5 ° (c 0.2, CH₂Cl₂); $[\alpha]^{25}_{D}$ (ref.⁶) -61.0 ° (c 0.2, CH₂Cl₂). ¹**H-RMN** (300 MHz, DMSO-*d*₆): δ 1.04 (s, 6H, tBu), 1.40 (s, 3H, tBu), 1.71 (m, 3H, α-CH₃), 4.89 (m, 1H, α-CH), 5.15 (m, 1H,

benzyl), 6.26 (m, 1H, benzyl), 6.52 (m, 2H, Ar), 7.00-7.34 (m, 8H, Ar).

(*3R*,*5R*,*6S*)-5,6-diphenyl-4-(*terc*-butoxycarbonyl)-3-methyl-2,3,5,6-tetrahydro-4*H*-1,4-oxazin-2-one (15)⁶.



White solid (81%). **M.p.** (hexane:AcOEt, 4:1): 198-199 °C. **HPLC** (Agilent, 10% to 100% of water in 10 min): 9.90 min (> 98% analytical purity). $[\alpha]^{rt}_{D}$ +67.0 ° (c 0.2, CH₂Cl₂); $[\alpha]^{25}_{D}$ -65.5 ° (c 0.2, CH₂Cl₂) of its enantiomer.¹**H-RMN** (300 MHz, DMSO-*d*₆): δ 1.04 (s, 6H, tBu), 1.40 (s, 3H, tBu), 1.65-1.76 (m, 3H, α -CH₃), 4.98-4.80 (q, *J* = 7.3 Hz, 1H, α -CH), 5.05-

5.27 (m, 1H, benzyl), 6.23-6.30 (m, 1H, benzyl), 6.47-6.56 (m, 2H, Ar), 7.00-7.31 (m, 8H, Ar).

(*3S*,*5S*,*6R*)-5,6-diphenyl-4-(*terc*-butoxycarbonyl)-3-methyl-3-(4'-pentenyl)-2,3,5,6tetrahydro-4*H*-1,4-oxazin-2-one (18)



To a solution of **14** (166 mg, 0.45 mmol) and freshly prepared 1-iodine-4-pentenyl⁷ (**16**, 2.26 mmol, 5.0 eq.) in dry THF (6 mL) at -40 °C, a solution of 1.0 M KN(TMS)₂ in THF (900 μ L, 0.90 mmol) was added dropwise for 10 min under argon atmosphere. Then, the mixture was stirred at this temperature

for 35 min. After the reaction was completed, the mixture was poured over AcOEt (10 mL), washed with H_2O (3 x 15 mL) and brine (1 x 15 mL), and dried over anh. Na₂SO₄. The organic phase was filtered and concentrated under reduced pressure. The resulting crude was purified by CCTLC (hexane:AcOEt, 5:1) to give a colorless oil (116 mg, 59%) that was identified as **18**. **HPLC** (Agilent, 10% to 100% of water in 10 min):

11.31 min (92% analytical purity). $[α]^{rt}{}_{D}$ + 25.2 ° (c 3.1, CH₂Cl₂). ¹H-RMN (400 MHz, DMSO-*d*₆): δ 1.04-1.85 (m, 14H, C_βH₂, α-CH₃, tBu), 2.07 (q, 2H, γ-CH₂ allyl, *J* = 7.0 Hz), 2.50 (m, 8H, α-CH₂), 5.03 (m, 2H, ε-CH₂ vinyl), 5.81 (dtd, 1H, δ-CH vinyl, *J* = 6.8, 6.6, 3.3 Hz), 6.23 (d, 2H, CH-Ph, *J* = 3.2 Hz), 6.87 (bs, 2H, Ar), 7.07-7.32 (m, 8H, Ar). ¹³C-RMN (100 MHz, DMSO-*d*₆): δ 23.8 (β-CH₂), 28.7 (CH₃, ^tBu, Boc), 33.8 (γ-CH₂), 64.2 (CH, CHPh), 115.7 (ε-CH₂), 126.0, 128.0, 128.5, 129.3, 135.6, 135.9, (C-Ar), 138.1 (δ-CH), 151.7 (C=O, Boc), 173.2 (C=O, lactone). EM (ESI +) *m/z*: 458.3 [M+Na]⁺ (100%), 336.3 [M-Boc]⁺ (80%), 195.1 [M-(1,2-diphenyl-1-hydroxyethane)]⁺ (70%). Elemental analysis (%) calculated for C₂₇H₃₃NO₄ C 74.45, H 7.64, N 3.22; found C 74.16, H 7.91, N 3.49.

(*3R*,*5R*,*6S*)-5,6-diphenyl-4-(*terc*-butoxycarbonyl)-3-methyl-3-(7'-octenyl)-2,3,5,6tetrahydro-4*H*-1,4-oxazin-2-one (19)



Following the described procedure for **18**, a solution of **15** (235 mg, 0.64 mmol) and freshly prepared 1-iodine-4-pentenyl⁷ (**17**, 1.94 mmol, 3.0 eq.) in dry THF (8 mL) was reacted with 1.0 M KN(TMS)₂ in THF (1.30 mL, 1.30 mmol, 2.0 eq.) for 45 min. The resulting crude was purified by

CCTLC (hexane:AcOEt, 6:1) to obtain 170 mg (56%) of a amorphous white solid identified as **19**. **HPLC** (Agilent, 10% to 100% of water in 10 min): 12.26 min (> 98% analytical purity). **[α]**^{**r**}_{**D**} -29.0 ° (c 3.4, CH₂Cl₂). ¹**H-RMN** (400 MHz, CDCl₃): δ 1.16-1.90 (m, 20H, β–CH₂, γ-CH₂, δ-CH₂, ε-CH₂, α-CH₃, tBu), 1.95-2.34 (m, 3H, CH₂ allyl, C₄H₂), 2.50 (m, 1H, C₄H₂), 4.94 (m, 2H, CH₂ vinyl), 5.78 (dtd, 1H, CH vinyl, J = 6.9, 6.6, 3.3 Hz), 5.96 (d, 2H, benzyl, J = 3.1 Hz), 6.86-7.43 (m, Ar, 10H). ¹³C-**RMN** (100 MHz, CDCl₃): δ 25.1 (β-CH₂), 28.6, 28.9 (CH₃, ¹Bu-Boc), 29.1 (γ-CH₂), 29.6 (δ-CH₂), 33.4 (CH₂ allyl), 39.3 (α-CH₂), 41.4 (α-CH₂), 64.2 (C, Cα), 80.6 (CH, benzyl), 81.2 (C, Boc), 82.0 (CH, benzyl), 114.5 (CH₂ vinyl), 125.9 , 127.9, 128.4, 129.1 (CH-Ar), 135.5 (C-Ar), 135.9 (C-Ar), 139.1 (CH, vinyl), 152.6 (C=O, Boc), 154.1 (C=O, Boc), 173.2 (C=O, lactone). **EM** (ESI +) *m/z*: 378.3 [M-Boc]⁺ (100%), 500.3 [M+Na]⁺ (90%). **Elemental analysis** (%) calculated for C₃₀H₃₉NO₄ C 75.44, H 8.23, N 2.92; found C 75.23, H 8.51, N 3.12.

Boc- α -(4'-pentenyl)-(S)-Ala-OH (20)



To a mixture of Na (237 mg, 10.38 mmol) in dry TFH saturated with NH₃ (6 mL) at -78 °C, a solution of **18** (348 mg, 0.81 mmol) and absolute EtOH (600 μ L) in dry THF (9 mL) was added dropwise. The reaction temperature was allowed to heat until -33 °C in 30

min, an excess of NH₄Cl was added and the mixture was stirred until it got room temperature. Then, H₂O (3 mL) was added and the organic phase was extracted with Et₂O (1 x 9 mL). The aqueous phase was acidified until pH = 2 with a solution of 3.0 N HCl and extracted with AcOEt (3 x 9 mL). The organic phases were combined, dried over anh. Na₂SO₄, filtered and concentrated under reduced pressure. The resulting crude was purified by CCTLC (CH₂Cl₂:MeOH, 95:5) to give 90 mg (43%) of a white solid identified as (*S*)-**20**. **M.p.** (CH₂Cl₂) 97-98 °C. **HPLC** (Agilent; 10% to 100% of water in 10 min): 7.87 min (83% analytical purity). $[\alpha]^{rt}_{D}$ + 12.7 ° (c 2.1, CH₂Cl₂). ¹**H-RMN** (400 MHz, acetone- d_6): δ 1.29-1.60 (m, 14H, α -CH₃, β -CH₂, Boc), 1.84 (td, 1H, γ -CH₂, *J* = 12.5, 5.0 Hz), 1.94-2.10 (m, 7H, acetona, γ -CH₂, α -CH₂), 4.96 (m, 2H, CH₂ vinyl), 5.79 (m, 1H, CH₂ vinyl), 5.80 (dtd, 1H, CH vinyl, *J* = 10.3, 6.7, 6.0 Hz), 6.06 (bs, 1H, NH). ¹³C-RMN (100 MHz, acetone- d_6): δ 24.3 (α -CH₃), 28,7 (CH₃, Boc), 34.6 (γ -CH₂), 37.0 (α -CH₂), 62.5 (C, α -C), 78.9 (C, Boc), 115.0 (CH₂, vinyl), 139.6 (CH, vinyl), 155.2 (C=O, Boc). **EM** (ESI +) *m/z*: 280.0 [M+Na]⁺ (100%), 180.1 [M-Boc+H]⁺ (40%), 224.1 [M-allyl+H]⁺ (50%).

Boc-α-(7'-octenyl)-(R)-Ala-OH (21)



The procedure described for **20** was followed from **19** (300 mg, 0.63 mmol). The resuting crude was purified by CCTLC (CH₂Cl₂:MeOH, 95:5) to give 108 mg (57%) of a white solid that was identified as (*R*)-**21**. **M.p.** (hexane) 180-181 °C. **HPLC** (Agilent, 10% to 100% of water in 10 min): 9.50 min (> 98% analytical purity). $[\alpha]^{ta}_{D}$ -6.5 ° (c 0.9, CH₂Cl₂). ¹**H-RMN** (400 MHz, acetone-*d*₆): δ 1.25-1.52 (m, 21H, β -CH₂, α -CH₃, γ -CH₂, δ -CH₂, ϵ -CH₂, ω -CH₂,

tBu), 1.84 (m, 1H, CH₂ allyclic), 1.94-2.14 (m, 6H, acetone, α-CH₂, CH₂ allyl), 4.94 (m,

2H, CH₂ vinyl), 5.80 (m, 1H, CH vinyl), 5.99 (bs, 1H, NH carbamate). ¹³C-RMN (100 MHz, acetone- d_6): δ 23.55 (α -CH₃), 24.6 (β -CH₂), 28.6 (CH₃, Boc), 29.6 (γ -CH₂, δ -CH₂), 30.3 (ϵ -CH₂), 34.5 (CH₂ allyl), 37.6 (α -CH₂), 59.8 (C, α -C), 79.0 (C, Boc), 114.8 (CH₂ vinyl), 139.9 (CH vinyl), 155.2 (C=O, Boc), 176.2 (C=O, acid). HRMS (ESI +) *m/z*: Calculated for C₁₆H₂₉NO₄ 299.2097; found [M+H]⁺ 300.2160.

Fmoc- α -(4'-pentenyl)-(S)-Ala-OH (3)⁸



To a solution of (*S*)-**20** (78 mg, 0.3 mmol) in CH₂Cl₂ (1.5 mL) at 0 °C was added TFA (1.5 mL). The mixture was stirred for 30 min at this temperature, concentrated under reduced pressure with oil bomb. The crude was the redisolved in a mixture of H₂O:acetona (1:1, 9 mL) and reacted with FmocOSu (111 mg, 0.33 mmol) and Na₂CO₃ (96 mg, 0.9 mmol) for 16 h at room temperature. The mixture was acidified until pH = 3 adding 0.1 N HCl. The solution was extracted with

AcOEt (3 x 6 mL), the organic phases dried over anh. Na₂SO₄, filtered, and concentrated under reduced pressure. The final crude was purified by CCTLC (CH₂Cl₂:MeOH, 95:5) to give 78 mg (69%) of a white foam identified as (*S*)-**3**⁸. **HPLC** (Agilent, 10% to 100% of water in 10 min): 10.65 min (> 98% analytical purity). $[\alpha]^{rt}_{D}$ +6.0 ° (c 1.1, CH₂Cl₂). ¹**H-RMN** (400 MHz, DMSO-*d*₆): δ 1.10-1.37 (m, 5H, α-CH₃, β-CH₂), 1.67 (m, 1H, γ-CH₂), 1.91 (m, 3H, γ-CH₂, α-CH₂), 4.21 (m, 2H, CH₂-Fmoc), 4.29 (m, 1H, CH-Fmoc), 4.93 (m, 2H, CH₂ vinyl), 5.73 (dtd, 1H, CH vinyl, *J* = 10.3, 6.7, 6.0 Hz), 6.94 (bs, 1H, NH), 7.32 (t, 2H, H_{2,7}-Fmoc, *J* = 7.5 Hz), 7.41 (t, 2H, H_{3,6}-Fmoc, *J* = 7.5 Hz), 7.65 (d, 2H, H_{1,8}-Fmoc, *J* = 7.5 Hz), 7.89 (d, 2H, H_{4,5}-Fmoc, *J* = 7.5 Hz). ¹³C-**RMN** (100 MHz, DMSO-*d*₆): δ 23.5 (β-CH₂), 28.9 (α-CH₃), 28.8 (CH₂), 33.5 (α-CH₂), 35.7 (γ-CH₂), 46.8 (CH-Fmoc), 127.0, 127.5 (C_{2,7}-Fmoc, C_{3,6}-Fmoc), 138.9 (CH vinyl), 140.7, 143.9, 144.0 (C-Fmoc), 153.6 (C=O, Fmoc), 176.2 (C=O, acid). **EM** (ESI +) *m/z*: 458.3 [M+K]⁺ (100%), 336.2 [M-(CH₂)₆CHCH₂+H]⁺ (100%), 380.2 [M-allyl+H]⁺ (60%), 195.1 [M-fulvene+H]⁺ (40%).

Fmoc-\alpha-(7'-octenyl)-(*R***)-Ala-OH (4)⁸**



The procedure described for **2** was followed from (*R*)-**21** (100 mg, 0.30 mmol). The final crude was purified by flash chromatography in silica gel (hexane:acetone, 1:1) to give 67 mg (53%) of a colorless oil that was identified as (*R*)-**4**⁸. **HPLC** (Agilent, 10% to 100% of water in 10 min): 10.65 min (> 98% analytical purity). $[\alpha]^{rt}_{D}$ -6.8 ° (c 0.9, CH₂Cl₂). ¹**H-RMN** (400 MHz, DMSO-*d*₆): δ 1.10-1.44 (m, 11H, β -CH₂, γ -CH₂, δ -CH₂, ϵ -CH₂, α -CH₃), 1.69 (m, 2H, α -CH₂), 1.99 (dt, 6.8 Hz, CH₂ allyl, *J* =

7.3 Hz), 4.22 (m, 3H, CH₂-Fmoc. CH-Fmoc), 4.96 (m, 2H, CH₂ vinyl), 5.77 (dtd, 1H, CH vinyl, J = 10.2, 6.6, 3.2 Hz), 7.32 (t, 2H, H_{2,7}-Fmoc, J = 7.5 Hz), 7.40 (t, 2H, H_{3,6}-Fmoc, J = 7.5 Hz), 7.71 (d, 2H, H_{1,8}-Fmoc, J = 7.5 Hz), 7.89 (d, 2H, H_{4,5}-Fmoc, J = 7.5 Hz), 12.40 (bs, 1H, acid). ¹³C-RMN (100 MHz, DMSO- d_6): δ 22.5 (α -CH₃), 23.2, 28.2, 28.4, 29.1 (β -CH₂, γ -CH₂, δ -CH₂, ϵ -CH₂), 33.17 (α -CH₂), 36.6 (CH₂ vinyl), 46.7 (CH-Fmoc), 58.3 (α -C, C), 65.2 (CH₂-Fmoc), 114.7 (CH₂ vinyl), 120.1, 125.3, 127.1, 127.6 (CH-Fmoc), 138.8 (CH, vinyl), 140.7, 143.9 (C-Fmoc), 154.7 (C=O, Fmoc), 175.4 (C=O, acid). **EM** (ESI +) *m/z*: 458.3 [M+K]⁺ (100%), 336.2 [M-(CH₂)₆CHCH₂+H]⁺ (100%), 380.2 [M-allyl+H]⁺ (60%), 195.1 [M-fulvene+H]⁺ (40%).

2.2.¹H- and ¹³C-NMR chemical shifts (δ) of stapled peptides **5a**, **8a** and **11**.



Stapled peptide 5a,b



Stapled peptide 8a,b

		-		
Residue	NH	а-СН	β-СН	Others
Pro1	-	4.25 (65.7)	2.00, 2.33 (33. <i>2</i>)	Ac 2.20 (<i>25.1</i>); γ-CH ₂ 2.01, 2.13 (<i>28.3</i>); δ-CH ₂ 3.64, 3.87 (<i>52.2</i>)
Glu2	9.32	4.13 (60.4)	2.06** (29.7)	2.37** (37.4);
lle3	7.70	3.82 (65.5)	2.08 (33.2)	δ-CH ₃ 0.91 (<i>13.1</i>); γ-CH ₃ 0.93 (<i>17.8</i>); γ-CH ₂ 1.18, 1.59 (<i>29.0</i>);
(D)- <u>Ala</u> 4	7.85	-	1.50, 2.31 (39.6)	γ-CH ₂ 1.18, 1.72 (26.3); δ-CH ₂ 1.11, 1.40 (35.5); ε-CH ₂ - ; φ-CH ₂ -; μ-CH ₂ 1.98, 2.10 (36.3); ν-CH 5.35 (-)
GIn5	8.12	4.01 (60.4)	2.14** (30.2)	γ-CH ₂ 2.38, 2.48 (<i>35.4</i>); CONH ₂ 6.67, 7.09
Ser6	7.73	4.29 (63.0)	3.99, 4.10 (64.1)	
Val7	8.59	3.77 (67.0)	2.13 (32.9)	γ-CH ₃ 0.98, 1.05 (22.6, 22.9)
Gly8	8.60	3.85, 3.91 (48.2)		
lle9	7.86	3.93 (65.4)	1.99 (39.2)	δ-CH ₃ 0.91 (<i>13.9</i>); γ-CH ₃ 0.97 (<i>18.1</i>); γ-CH ₂ 1.25, 1.76 (29.9)
Ser10	7.59	4.11 (65.6)	3.97** (64.1)	
				β–CH ₃ -
<u>Ala11</u>	8.25	-	1.74, 1.98 (42.7)	γ-CH ₂ 1.34** (-); δ-CH ₂ 1.87, 1.95 (35.5); ε-CH 5.43 (-);
Lys12	7.57	4.16 (59.0)	1.88** (<i>33.8</i>)	γ-CH ₂ 1.52, 1.62 (26.1); δ-CH ₂ 1.33 (30.1); ε-CH ₂ 3.00 (43.2); NH ₂ -
Nie13	7.99	4.17 (58.7)	1.88** (<i>34.5</i>)	γ-CH₂ 1.51** (<i>31</i> .7); δ-CH₂ 1.33** (<i>25.4</i>); ε-CH₃ 0.88 (<i>16.6</i>); CONH₂ terminal 6.92, 7.33

Table S3. ¹*H*- and ¹³*C*-*NMR* chemical shifts (δ , ppm from DSS) of stapled peptide **5a** in 30% TFE in H₂O/D₂O 9:1 v/v at pH 5.5 and 25°C.

Residuo	NH	а-СН	<i>β-CH</i>	Others
				Ac 2.21 (24.7);
Pro1	-	4.27 (66.1)	1.99, 2.36 (33.6)	γ-CH ₂ 2.03, 2.16 (-);
				δ-CH ₂ 3.63, 3.88 (-)
Glu2	9.00	4.12 (60.8)	2.08, 2.08 (-)	2.41, 2.49 (-)
				δ-CH ₃ 0.94 (12.7);
Ile3	7.64	3.79 (65.8)	2.10 (38.9)	γ-CH ₃ 0.94 (17.2);
				γ-CH ₂ 1.17, 1.60 (-)
				β-CH ₃ 1.51 (22.3);
AlaA	7.81		1.03.2.13()	γ-CH ₂ 1.69, 1.69 (-);
<u>Auu</u> 4	7.01	-	1.95, 2.15 (-)	δ-CH ₂ 1.71, 2.07 (-);
				ε-CH 5.35 (-)
Cln5	8 50	4 07 (61 2)	210, 227()	γ-CH ₂ 2.43, 2.60 (35.7);
Gills	8.50	4.07 (01.3)	2.19, 2.27 (-)	CONH ₂ 6.32, 6.49
Ser6	7.74	4.23 (63.4)	4.06, 4.06 (-)	
Val7	7.75	3.64 (68.6)	2.38 (32.9)	γ-CH ₃ 0.96, 1.03 (21.1, 22.6)
				β-CH ₃ 1.49 (21.4);
41-0	0.27		151 218 ()	γ-CH ₂ 1.52, 1.52 (-);
<u>Ala</u> 8	······································	δ-CH ₂ 1.66, 2.17 (-);		
				ε-CH 5.48 (-)
				δ-CH ₃ 0.90 (13.6);
Ile9	8.45	3.75 (66.9)	1.94 (39.4)	γ-CH ₃ 0.98 (<i>18.0</i>);
				γ-CH ₂ 1.23, 1.50 (-)
Ser10	7.84	4.20 (63.8)	4.05, 4.05 (-)	
				γ-CH ₂ 1.35, 1.60 (29.0)
Nle11	8.22	4.18 (60.7)	1.87, 1.97 (34.4)	δ-CH ₂ 1.30, 1.30 (25.4);
				ε-CH ₂ 0.86 (16.1)
				γ-CH ₂ 1.50, 1.58 (25.6);
Lys12	8.17	4.24 (59.0)	2.01, 2.07 (-)	δ-CH ₂ 1.74, 1.74 (29.6);
				ε-CH ₂ 3.01, 3.01 (43.3)
				γ-CH ₂ 1.51,1.51 (-);
Nle13	8.45	4.20 (59.3)	1.89, 1.89 (34.8)	δ-CH ₂ 1.33, 1.33 (25.3);
		ε-CH ₃ 0.89 (16.1);		

Table S4. ¹*H*- and ¹³*C*-*NMR* chemical shifts (δ , ppm from DSS) of stapled peptide **8a** in 30% TFE in H₂O/D₂O 9:1 v/v at pH 5.5 and 25°C.

Table S5.	^{1}H -and ^{13}O	C-NMR ch	nemical s	shifts (ð,	ppm fron	ı DSS)	of stapled	peptide	11	in
30% TFE in	$n H_2 O/D_2 C$) 9:1 v/v a	at pH 5.5	5 and 25°	С.					

Residue	HN	а-СН	β-СН	Others
Pro1	-	4.36 (65.0)	2.03, 2.40 (32.7)	Ac 2.23 (24.5); γ-CH ₂ 1.99, 2.04 (-); δ- CH ₂ 3.67, 3.91 (-)
Glu2	9.42	4.17 (59.8)	2.09, 2.09 (28.8)	γ-CH ₂ 2.41, 2.41 (<i>36.4</i>)
				δ-CH ₃ 0.94 (12.4);
Ile3	7.71	3.85 (64.6)	2.08 (38.0)	γ-CH ₃ 0.93 (16.9);
				γ-CH ₂ 1.21, 1.63 (-)
<u>Glu4</u>	7.90	3.79 (61.5)	1.90, 2.57 (-)	γ-CH ₂ 2.31, 2.57 (34.8)
Ch-5	0.10	2.80 (50.8)		γ-CH ₂ 2.48, 2.50 (34.8);
GIII5	8.18	5.89 (59.8)	2.12, 2.22 (-)	CONH ₂ 6.65, 7.30
Ser6	7.77	4.22 (-)	4.01, 4.18 (-)	
Val7	8.28	3.64 (67.5)	2.32 (32.0)	γ-CH ₃ 0.97, 1.07 (21.2, 22.4)
				γ-CH ₂ 1.16, 1.43 (-);
<u>Lys8</u>	7.97	3.88 (-)	1.82, 1.91 (-)	δ-CH ₂ 1.65, 1.65 (-);
				ε-CH 2.67, 3.56 (42.7)
				δ-CH ₃ 0.87 (13.0);
Ile9	8.29	3.74 (65.8)	1.94 (38.5)	γ-CH ₃ 0.96 (17.3);
				γ-CH ₂ 1.17, 1.83 (-)
Ser10	8.08	4.18 (-)	4.00, 4.14 (-)	
				γ-CH ₂ 1.62, 1.62 (31.2)
Nle11	8.18	4.11 (59.5)	1.86, 1.92 (-)	δ-CH ₂ 1.31, 1.31 (24.9);
				ε-CH ₂ 0.86 (15.7)
				γ-CH ₂ 1.52, 1.59 (25.2);
Lyc12	7.06	A 18 (59 I)		δ-CH ₂ 1.73, 1.73 (29.3);
Lysiz	7.90	4.18 (36.1)	2.00, 2.04 (-)	ε-CH ₂ 3.01, 3.01 (42.5);
				ζ-NH ₂ 7,04
				γ-CH ₂ 1.50, 1.50 (-);
NIo13	8 10	A 17 ()	182 187()	δ-CH ₂ 1.32, 1.32 (24.8);
111015	0.17	4.17 (-)	1.02, 1.07 (-)	ε-CH ₃ 0.88 (15.8);
			CONH ₂ 6.90, 7.19	